Stay updated with breaking news from Oblte. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Belite Bio (NASDAQ:BLTE – Free Report) had its price target boosted by HC Wainwright from $55.00 to $59.00 in a research report report published on Monday, Benzinga reports. They currently have a buy rating on the stock. A number of other analysts have also weighed in on BLTE. SVB Securities started coverage on shares of […]
Belite Bio, Inc (NASDAQ:BLTE – Get Free Report) saw unusually-high trading volume on Tuesday after HC Wainwright raised their price target on the stock from $55.00 to $59.00. HC Wainwright currently has a buy rating on the stock. Approximately 97,119 shares were traded during trading, an increase of 77% from the previous session’s volume of […]
Shares of Belite Bio, Inc (NASDAQ:BLTE – Get Free Report) have earned an average rating of “Buy” from the six brokerages that are covering the stock, Marketbeat.com reports. Six analysts have rated the stock with a buy rating. The average twelve-month price objective among brokerages that have covered the stock in the last year is […]
Belite Bio, Inc (NASDAQ:BLTE – Get Free Report) shares saw an uptick in trading volume on Friday . 268,388 shares were traded during trading, an increase of 496% from the previous session’s volume of 45,016 shares.The stock last traded at $33.68 and had previously closed at $32.35. Analyst Upgrades and Downgrades BLTE has been the […]
Belite Bio (NASDAQ:BLTE – Get Free Report) and Foghorn Therapeutics (NASDAQ:FHTX – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, dividends, risk, valuation, earnings and institutional ownership. Institutional & Insider Ownership 3.8% of Belite […]